COGT Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
117.2M
+14.2%
102.6M
-0.9%
103.6M
+4.1%
99.5M
+19.4%
83.4M
R&D
75.1M
+6.1%
70.8M
-6.0%
75.4M
-0.3%
75.6M
+9.5%
69.0M
SG&A
42.1M
+32.2%
31.8M
+12.7%
28.2M
+18.0%
23.9M
+66.6%
14.4M
Operating Income
-117184000
-14.2%
-102638000
+0.9%
-103607000
-4.1%
-99493000
-19.4%
-83355000
EBITDA
-116612000
-14.4%
-101897000
+1.1%
-102981000
-4.2%
-98865000
-19.5%
-82714000
Net Income
-111426000
-15.6%
-96405000
+1.0%
-97352000
+5.0%
-102492000
-26.6%
-80930000
EPS (Basic)
$-0.59
-13.5%
$-0.52
+1.9%
$-0.53
+10.2%
$-0.59
-18.0%
$-0.50
EPS (Diluted)
$-0.59
-13.5%
$-0.52
+1.9%
$-0.53
+10.2%
$-0.59
-18.0%
$-0.50
Shares (Diluted)
173.1M
+1.2%
171.0M
+5.4%
162.2M
+7.9%
150.3M
+9.2%
137.6M
Cogent Biosciences (COGT) — Financials